Low cytomegalovirus-specific T-cell counts at reactivation are associated with progression to high-level viremia or disease in seropositive recipients of hematopoietic cell grafts from seropositive but not seronegative donors

Cytotherapy

Volumn 14, Issue 2, 2012, Pages 194-204

  Hoegh Petersen, Mette ^a   Roa, Lina ^a   Liu, Yiping ^a   Zhou, Feng ^a   Ugarte Torres, Alejandra ^a   Louie, Polly ^b   Fonseca, Kevin ^c   Khan, Faisal ^a   Russell, James A ^b   Storek, Jan ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

Author keywords

Cytomegalovirus reactivation; Cytomegalovirus specific T cells; Hematopoietic cell transplantation; Pre emptive ganciclovir treatment

Indexed keywords

GAMMA INTERFERON; GANCICLOVIR; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; VIREMIA; VIRUS REACTIVATION;

EID: 84862907692     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.634402     Document Type: Article

References (49)

1. Zaia JA. Cytomegalovirus Infection. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG. Thomas' Hematopoietic Cell Transplantation, 4th edition, Wiley-Blackwell, West Sussex, UK, 2008;1367-1381.
2. George B, Pati N, Gilroy N, Ratnamohan M, Huang G, Kerridge I, et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis. 2010;12(4):322-9.
3. Storek J, Geddes M, Khan F, Huard B, Helg C, Chalandon Y, et al. Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. Semin Immun-opathol. 2008;30:425-37.
4. + T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection. Haematologica. 2008;93:248-56. (Pubitemid 351397713)
5. + CMV-specific T cells protects against CMV reactivation following allo geneic SCT Bone Marrow Transplant. 2009;43:853-61.
6. + T cells and control of HCMV replication after allogeneic stem cell transplantation. J Virol. 2008;82:10143-52.
7. Zhou W, Longmate J, Lacey SF, Palmer JM, Gallez-Hawkins G, Thao L, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood. 2009; 113:6465-76.
8. + T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74:211-20. (Pubitemid 352007318)
9. + T cells. Blood. 2002;100:3690-7. (Pubitemid 35303940)
10. Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakra-barti S, Cortez K, et al. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. Biol Blood Marrow Transplant. 2004;10:49-57. (Pubitemid 38145739)
11. Widmann T, Sester U, Gartner BC, Schubert J, Pfreundschuh M, Kohler H, et al. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS One. 2008;3:e3634.
12. Barron MA, Gao D, Springer KL, Patterson JA, Brunvand MW, McSweeney PA, et al. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2009;49:1777-83.
13. + T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 2006;108:1406-12. (Pubitemid 44232045)
14. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2010;45:543-9.
15. Avetisyan G, Larsson K, Aschan J, Nilsson C, Hassan M, Ljung-man P. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;38:687-92. (Pubitemid 44669684)
16. Scheinberg P, Melenhorst JJ, Brenchley JM, Hill BJ, Hensel NF, Chattopadhyay PK, et al. The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor. Blood. 2009;114:5071-80.
17. Pastore D, Delia M, Mestice A, Perrone T, Carluccio P, Gau-dio F, et al. Recovery of CMV-specific CD8(+) T cells and T regs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2011 Apr;17(4):550-7 (It was ePublished in 2010).
18. Morita-Hoshi Y, Heike Y, Kawakami M, Sugita T, Miura O, Kim SW, et al. Functional analysis of cytomegalovirus-specific T lymphocytes compared to tetramer assay in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008;41:515-21. (Pubitemid 351472142)
19. + T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8:501-11. (Pubitemid 35174824)
20. Boeckh M. Changing patterns in the risk of cytomegalovirus disease and treatment-related outcomes in the era of preemptive antiviral therapy. Bone Marrow Transplant. 2006;37(Suppl 1):S31.
21. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: risk factors and outcome. Blood. 1997;90:2502-8. (Pubitemid 27392736)
22. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601-7.
23. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load > or = 10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 2006;37:51-6. (Pubitemid 43135315)
24. Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood. 2007;110:2757-60. (Pubitemid 47523202)
25. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174:1037-45. (Pubitemid 40094300)
26. + T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation. Am J Transplant. 2009;9:794-803.
27. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMchael AJ, Whittle HC, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008;38:350-63.
28. Choi SM, Lee DG, Choi JH, Yoo JH, Kim YJ, Park SH, et al. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea. Int J Hematol. 2006;83:277-8. (Pubitemid 44228008)
29. Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT Bone Marrow Trans-plant. 2007;40:865-9. (Pubitemid 350020321)
30. Russell JA, Turner AR, Larratt L, Chaudhry A, Morris D, Brown C, et al. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis. Biol Blood Marrow Transplant. 2007;13:299-306.
31. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fl udarab-ine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007;13:814-21. (Pubitemid 46902436)
32. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-8.
33. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-56. (Pubitemid 41754712)
34. Pang XL, Chui L, Fenton J, LeBlanc B, Preiksaitis JK. Comparison of LightCycler-based PCR, COBAS amplicor CMV monitor, and pp65 antigenemia assays for quantitative measurement of cytomegalovirus viral load in peripheral blood specimens from patients after solid organ transplantation. J Clin Microbiol. 2003;41:3167-74. (Pubitemid 36842317)
35. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-7. (Pubitemid 34289682)
36. Ugarte-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, et al. Donor serostatus impacts cytomeg-alovirus-specific immunity, cytomegaloviral disease incidence and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011;46(8):1104-12.
37. Zelini P, Lilleri D, Comolli G, Rognoni V, Chiesa A, Fornara C, et al. Human cytomegalovirus-specific CD4(+) and CD8(+) T-cell response determination: comparison of short-term (24h) assays vs long-term (7-day) infected dendritic cell assay in the immunocompetent and the immunocompromised host. Clin Immunol. 2010;136:269-81.
38. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116:4360-7.
39. Mcklethwaite KP, Clancy L, Sandher U, Hansen AM, Blyth E, Antonenas V, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112:3974-81.
40. + cytotoxic T-cell responses during chronic viral infection. J Virol. 1994;68:8056-63. (Pubitemid 24362694)
41. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-44.
42. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16:1309-14.
43. Hakki M, Riddell SR, Storek J, Carter RA, Stevens-Ayers T, Sudour P, et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102:3060-7. (Pubitemid 37248884)
44. Liberman AC, Druker J, Refojo D, Holsboer F, Arzt E. Glucocorticoids inhibit GATA-3 phosphorylation and activity in T cells. FASEB J. 2009;23:1558-71.
45. Knight A, Madrigal AJ, Grace S, Sivakumaran J, Kottaridis P, Mackinnon S, et al. The role of Vdelta2-negative gammadelta T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116:2164-72.
46. Schmidt-Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol. 2010;91:877-85.
47. Chen C, Busson M, Rocha V, Appert ML, Lepage V, Dulphy N, et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006;38:437-44. (Pubitemid 44340375)
48. Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, et al. Donor KIR genotype has a major infl uence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006;107:1230-2. (Pubitemid 43156330)
49. Zaia JA, Sun JY, Gallez-Hawkins GM, Thao L, Oki A, Lacey SF, et al. The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2009;15:315-25.